الفهرس 
List of contents
List of tablesOnly 14 pages are availabe for public view
 |  | from | 110 |  |  |
| | | from | 110 | | |
Abstract
This case control study was carried out in Clinical Oncology and Nuclear Medicine Department at Assiut University Hospital. The study was conducted between October 2019 till December 2020 and follow up one year The aim of the study to evaluate FGL2 expression and to explore the prognostic relevance of FGL2 in glioblastoma by relating the level of their expression to some established prognostic factors such as:(patient age, multifocal tumor, total or subtotal excision, tumor regrowth, karnofsky performance score and histopathological feature as: (necrosis) and follow up data of the patients (PFS) and overall (OS) Patient elegible for the study are those whom age >18 years old, Pathologically proven high grade glioma, Total or subtotal resection of the tumor, and Patients received concurrent radiation therapy with temozolomide followed by adjuvant temozolamide for 6 months. We found in our study Mean age of enrolled patients was 48.88 year with range between 19 and 68 years. Majority (75%) of patients were males and 15 (25%) patients were females Mean long axis of the lesion was 4.58 ± 1.29 cm. The most frequently affected lobes were parietal lobes (28.3%) and temporal lobe (21.7%). Patient classified according to Intensity of FGL2 was, negative, mild, moderate and strong was 7,16 (26.7%), 20 (33.3%) and 17 (28.3%) patients, respectively., it was found that intensity of FGL2 was more among patients with disease progression. All patients with progression had either moderate intensity (46.2%) or strong intensity (53.8%). Seven (14.9%) patients without disease progression had negative FGL2 expression. It was found that disease free progression was significantly decreased with increasing in the intensity of FGL2 where patients with strong intensity had the lowest DFP (14 month) while patients with negative FGL2 and mild intensity had the highest DFP It was found that percentage of FGL2 was significantly higher among died patients. It was found that overall survival was significantly decreased with increasing in the intensity of FGL2 where patients with strong intensity had the lowest overall survival (19 month) while patients with negative FGL2 and mild intensity had the highest DFP (27and 26 month, respectively).